View Older Stories View More Recent Stories

Sep 29, 2022 04:31PM Vanda Pharmaceuticals (VNDA), OliPass Announce Strategic Partnership to Develop Antisense Oligonucleotide Therapeutics
Sep 29, 2022 04:30PM Vanda Pharmaceuticals and OliPass Announce Strategic Partnership to Develop Antisense Oligonucleotide Therapeutics
Sep 8, 2022 06:00PM Vanda Pharmaceuticals Announces Participation in the H.C. Wainwright Global Investment Conference
Sep 7, 2022 06:38PM VANDA PHARMACEUTICALS ANNOUNCES NOTICE OF OPPORTUNITY FOR AN FDA HEARING ON THE sNDA FOR HETLIOZ® IN JET LAG DISORDER
Aug 3, 2022 04:01PM Vanda Pharmaceuticals Reports Second Quarter 2022 Financial Results
Jul 27, 2022 05:30PM Vanda Pharmaceuticals to Announce Second Quarter 2022 Financial Results on August 3, 2022
Jun 2, 2022 04:30PM Vanda Pharmaceuticals Announces Participation in the Jefferies 2022 Global Healthcare Conference
May 31, 2022 06:00PM Vanda Pharmaceuticals Announces Presentations at SLEEP 2022
May 19, 2022 07:00PM Vanda Pharmaceuticals Announces Presentations at DDW 2022
May 5, 2022 04:10PM Vanda Pharmaceuticals Reports First Quarter 2022 Financial Results
May 4, 2022 04:30PM Vanda Pharmaceuticals Announces Participation in the BofA Securities 2022 Healthcare Conference
Apr 28, 2022 05:00PM Vanda Pharmaceuticals to Announce First Quarter 2022 Financial Results on May 5, 2022
Feb 23, 2022 04:01PM Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
Feb 17, 2022 06:00PM Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022
Feb 4, 2022 07:01AM Vanda Pharmaceuticals (VNDA) Phase III Study of Tradipitant in Gastroparesis Did Not Meet Primary Endpoint
Feb 4, 2022 07:00AM Vanda Pharmaceuticals Reports Results from the Phase III Study of Tradipitant in Gastroparesis
Jan 14, 2022 08:36AM Vanda Pharmaceuticals (VNDA) Settles HETLIOZ Patent Litigation with MSN
Jan 14, 2022 08:35AM Vanda Pharmaceuticals Settles HETLIOZ® Patent Litigation with MSN
Nov 10, 2021 06:30PM Vanda Pharmaceuticals Announces Participation at November 2021 Investor Conferences
Nov 3, 2021 04:01PM Vanda Pharmaceuticals Reports Third Quarter 2021 Financial Results
Oct 27, 2021 05:30PM Vanda Pharmaceuticals to Announce Third Quarter 2021 Financial Results on November 3, 2021
Oct 14, 2021 04:30PM Vanda Pharmaceuticals Announces Participation at Evercore ISI's Catalyst Day
Sep 7, 2021 08:30PM Vanda Pharmaceuticals Announces Participation at the Citi 16th Annual BioPharma Virtual Conference
Aug 3, 2021 07:00AM Vanda Pharmaceuticals Closes Enrollment In The ODYSSEY Study Comparing Tradipitant And Placebo In Hospitalized COVID-19 Pneumonia Patients
Jul 28, 2021 04:01PM Vanda Pharmaceuticals Reports Second Quarter 2021 Financial Results
Jul 21, 2021 04:30PM Vanda Pharmaceuticals to Announce Second Quarter 2021 Financial Results on July 28, 2021
May 12, 2021 04:30PM Vanda Pharmaceuticals Announces Participation at Upcoming 2021 Investor Conferences
May 5, 2021 04:01PM Vanda Pharmaceuticals Reports First Quarter 2021 Financial Results
Apr 20, 2021 04:30PM Vanda Pharmaceuticals to Announce First Quarter 2021 Financial Results on May 5, 2021
Feb 10, 2021 04:01PM Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results
Feb 2, 2021 04:30PM Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results on February 10, 2021
Dec 2, 2020 09:17AM Vanda Pharmaceuticals (VNDA) Announces FDA Approval of HETLIOZ for Sleep Disturbances
Dec 1, 2020 06:22PM FDA Approves HETLIOZ® (tasimelteon) for the Treatment of Nighttime Sleep Disturbances in Smith-Magenis Syndrome
Oct 28, 2020 04:01PM Vanda Pharmaceuticals Reports Third Quarter 2020 Financial Results
Oct 26, 2020 04:02PM Vanda Pharmaceuticals (VNDA) Gains FDA Approval to Proceed with IND for VSJ-110 for Allergic Conjunctivitis
Oct 26, 2020 04:01PM Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VSJ-110 for Allergic Conjunctivitis
Oct 21, 2020 04:45PM Vanda Pharmaceuticals to Announce Third Quarter 2020 Financial Results on October 28, 2020
Sep 1, 2020 06:21AM Vanda Pharmaceuticals (VNDA) Provides Update on Tradipitant Development Program
Aug 31, 2020 06:30PM Vanda Pharmaceuticals Provides Update on Tradipitant Development Program
Aug 18, 2020 07:03AM Vanda Pharma (VNDA) Announces Interim Analysis from ODYSSEY Study Shows Tradipitant may Accelerate Clinical Improvement in Patients with COVID-19 Pneumonia
Aug 18, 2020 07:00AM Vanda Pharmaceuticals' Interim Analysis from ODYSSEY Study Shows Tradipitant may Accelerate Clinical Improvement in Patients with COVID-19 Pneumonia
Aug 5, 2020 04:01PM Vanda Pharmaceuticals Reports Second Quarter 2020 Financial Results
Aug 3, 2020 07:05AM Vanda Pharmaceuticals (VNDA) Applications for HETLIOZ Accepted by FDA for Priority Review
Aug 3, 2020 07:00AM FDA Accepts and Grants Priority Review of Vanda's Applications for HETLIOZ® (tasimelteon) in the Treatment of Smith-Magenis Syndrome
Jul 29, 2020 05:00PM Vanda Pharmaceuticals to Announce Second Quarter 2020 Financial Results on August 5, 2020
Jul 13, 2020 04:31PM Vanda Pharmaceuticals (VNDA) announces FDA grants authorization for Individual Patient Expanded Access Protocol for the use of tradipitant for gastroparesis
Jul 13, 2020 04:30PM FDA grants authorization for Individual Patient Expanded Access Protocol for the use of tradipitant for gastroparesis
May 26, 2020 07:00AM Vanda Pharmaceuticals Announces Virtual 2020 Stockholder Meeting
May 20, 2020 05:20PM Vanda Pharmaceuticals Wins Motion To Dismiss False Claims Act Lawsuit
May 20, 2020 10:46AM Vanda Pharmaceuticals (VNDA) CEO's Proposal on Clinical Trial Data Sharing, COVID-19 and Remdesivir
View More Recent Stories View Older Stories